| # | Title | Journal | Year | Citations |
|---|
| 1 | Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines | Journal of Extracellular Vesicles | 2018 | 6,961 |
| 2 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | Autophagy | 2016 | 4,701 |
| 3 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2018 | 4,701 |
| 4 | Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer | New England Journal of Medicine | 2002 | 3,765 |
| 5 | Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer | Journal of Clinical Oncology | 2000 | 3,563 |
| 6 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,077 |
| 7 | Genomic Classification and Prognosis in Acute Myeloid Leukemia | New England Journal of Medicine | 2016 | 3,067 |
| 8 | Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma | New England Journal of Medicine | 2017 | 2,677 |
| 9 | A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia | New England Journal of Medicine | 2005 | 2,255 |
| 10 | Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards | Nature Communications | 2016 | 2,076 |
| 11 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet, The | 2012 | 1,752 |
| 12 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | New England Journal of Medicine | 2017 | 1,752 |
| 13 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial | Lancet, The | 2017 | 1,728 |
| 14 | Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases | Journal of Thoracic and Cardiovascular Surgery | 1997 | 1,451 |
| 15 | Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections | Journal of Pathology | 1992 | 1,424 |
| 16 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2017 | 1,388 |
| 17 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,261 |
| 18 | The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells | Cell | 2011 | 1,115 |
| 19 | Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional Study | Journal of Clinical Oncology | 2004 | 1,089 |
| 20 | Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project | Lancet, The | 2014 | 1,077 |
| 21 | Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC | Lancet Oncology, The | 2012 | 1,017 |
| 22 | Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma | Cancer | 1996 | 1,010 |
| 23 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | Lancet, The | 2018 | 984 |
| 24 | Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women | Journal of the National Cancer Institute | 2003 | 963 |
| 25 | Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study | Lancet, The | 2016 | 962 |
| 26 | PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas | Cell | 1990 | 905 |
| 27 | Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | Journal of Clinical Oncology | 2012 | 873 |
| 28 | Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies | Lancet, The | 2018 | 858 |
| 29 | Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women | Lancet, The | 2017 | 825 |
| 30 | Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study | Journal of Clinical Oncology | 2007 | 799 |
| 31 | Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project | Blood | 2010 | 784 |
| 32 | Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer | Journal of the National Cancer Institute | 2007 | 769 |
| 33 | Morphine and alternative opioids in cancer pain: the EAPC recommendations | British Journal of Cancer | 2001 | 759 |
| 34 | EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary | European Journal of Cancer | 2009 | 740 |
| 35 | Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections | Journal of Pathology | 1993 | 735 |
| 36 | Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment | Proceedings of the National Academy of Sciences of the United States of America | 2009 | 733 |
| 37 | NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations | Cancer Research | 2008 | 726 |
| 38 | Role of Macrophage Targeting in the Antitumor Activity of Trabectedin | Cancer Cell | 2013 | 721 |
| 39 | Radiotherapy after Breast-Preserving Surgery in Women with Localized Cancer of the Breast | New England Journal of Medicine | 1993 | 714 |
| 40 | Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2020 | 710 |
| 41 | Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer | 2019 | 702 |
| 42 | Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Lancet Oncology, The | 2014 | 695 |
| 43 | miR-221 overexpression contributes to liver tumorigenesis | Proceedings of the National Academy of Sciences of the United States of America | 2010 | 679 |
| 44 | Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer | Journal of Clinical Oncology | 2011 | 669 |
| 45 | ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology | Clinical Nutrition | 2006 | 665 |
| 46 | Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. | Proceedings of the National Academy of Sciences of the United States of America | 1989 | 663 |
| 47 | Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles | Journal of Experimental Medicine | 2002 | 660 |
| 48 | Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features | Gastroenterology | 2017 | 650 |
| 49 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) | Cancer Discovery | 2017 | 647 |
| 50 | Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 641 |
